GlassScriptPhysician profile
Mushtaq Ahmed
NPI 1033137591
$9,718.68
in general payments reported to CMS, 2019-2025
40 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $771 · 2021: $922 · 2022: $1,353 · 2023: $1,690 · 2024: $2,041 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,738 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,738.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,408.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,585.81 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,436.04 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Inspire Medical Systems, INC. | $548.04 | 2019-2025 | Inspire |
| Genzyme Corporation | $506.00 | 2020-2025 | |
| United Therapeutics Corporation | $377.61 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $337.11 | 2020-2025 | Prolastin-C Liquid |
| Amgen INC. | $321.23 | 2024-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $245.25 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $175.00 | 2020 | |
| Baxter Healthcare | $167.44 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $156.30 | 2024-2025 | Glassia |
| Insmed, INC. | $152.12 | 2021-2025 | Arikayce |
| Verona Pharma, INC. | $119.72 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $117.41 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $115.87 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Angiodynamics, INC. | $114.64 | 2025 | Auryon Laser System 100-120 Vac |
| Pfizer INC. | $112.02 | 2023-2025 | |
| Advanced Respiratory, INC | $110.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.59 | 2019-2025 | Winrevair, Capvaxive |
| Electromed, INC. | $69.65 | 2021 | |
| Apria Healthcare LLC | $61.77 | 2021 | |
| Mylan Specialty L.P. | $53.12 | 2019-2023 | Yupelri |
| Vifor Pharma, INC. | $50.79 | 2024 | Zemaira |
| Lilly USA, LLC | $38.15 | 2024-2025 | Zepbound, Mounjaro |
| Sunovion Pharmaceuticals INC. | $36.23 | 2019-2022 | |
| Resmed Corp | $32.36 | 2019 | |
| Abbvie INC. | $25.45 | 2022 | |
| Novo Nordisk INC | $23.92 | 2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $18.77 | 2025 | |
| Shield Therapeutics INC | $17.05 | 2025 | |
| Genentech USA, INC. | $16.89 | 2019 | |
| Phadia US INC. | $15.34 | 2021 | |
| Horizon Therapeutics Plc | $15.03 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.62 | 2021 | |
| Allergan, INC. | $14.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.78 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mushtaq Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.